5:18 PM
 | 
May 16, 2014
 |  BC Extra  |  Clinical News

Kamada slides on AAT miss, still planning MAA submission

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) fell $4.74 (34%) to $9.08 in New York on Friday after reporting that twice-daily aerosolized alpha-1 antitrypsin (AAT) missed the primary endpoint in a 168-patient Phase II/III...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >